Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy

Abstract excerpt

Doxorubicin and the ERBB2 targeted therapy, trastuzumab, are routinely used in the treatment of HER2+ breast cancer. In mouse models, doxorubicin is known to cause cardiomyopathy and conditional cardiac knock out of Erbb2 results in dilated cardiomyopathy and increased sensitivity to doxorubicin-induced cell death. In humans, these drugs also result in cardiac phenotypes, but severity and reversibility is highly...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chemotherapy-induced cardiotoxicity and mitigation
• Share to HER2/EGFR in Cancer Research
• Share to Peptidase Inhibition and Analysis